¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"non REM"¿¡ ´ëÇÑ °æºÏ´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­³»°úÇб³½Ç »çÀü ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • non-Hodgkin lymphoma
    ºñÈ£ÁöŲ ¸²ÇÁÁ¾
  • non-inflammatory
    ºñ¿°Áõ¼º
  • non-injury controlled population
    ºñ¿Ü»ó¼º ȯÀÚ
  • non-invasive
    ºñ°üÇ÷Àû, ºñħ¹ü¼º
  • non-keratinized squamous cell carcinoma
    ºñ°¢È­¼º ÆíÆò »óÇÇ ¼¼Æ÷ ¾Ï
  • non-malignant
    ºñ¾Ç¼º
  • non-neoplastic
    ºñ½Å»ý¹°¼º
  • non-nociceptive A delta C primary afferent
    ºñÄ§ÇØ ¼ö¿ë¼º A µ¨Å¸ C ÀÏÂ÷ ±¸½É ½Å°æ, ºñÀ¯ÇØ ¼ö¿ë¼º A µ¨Å¸ C ÀÏÂ÷ ±¸½É ½Å°æ
  • non-nociceptive cell
    ºñÄ§ÇØ ¼ö¿ë¼º ¼¼Æ÷, ºñÀ¯ÇØ ¼ö¿ë¼º ¼¼Æ÷
  • non-nociceptive myelinated afferent
    ºñÄ§ÇØ ¼ö¿ë¼º À¯¼ö ±¸½É ¼¶À¯, ºñÀ¯ÇØ ¼ö¿ë¼º À¯¼ö ±¸½É ¼¶À¯
  • non-nociceptive myelinated primary afferent
    ºñÄ§ÇØ ¼ö¿ë¼º ÀÏÂ÷ ±¸½É ¼¶À¯, ºñÀ¯ÇØ ¼ö¿ë¼º ÀÏÂ÷ ±¸½É ¼¶À¯
  • non-noxious cutaneous stimulation system
    ºñÀ¯Çؼº ÇǺΠÀڱذè
  • non-odontogenic
    ºñÄ¡¼º
  • non-opiate
    ºñ¾ÆÆí¼º
  • non-painful cutaneous stimulation system
    ºñÅëÁõ¼º Àڱذè
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
ÅëÇÕ°Ë»ö ¿Ï·á